UY34525A - Un medicamento inhalable - Google Patents

Un medicamento inhalable

Info

Publication number
UY34525A
UY34525A UY0001034525A UY34525A UY34525A UY 34525 A UY34525 A UY 34525A UY 0001034525 A UY0001034525 A UY 0001034525A UY 34525 A UY34525 A UY 34525A UY 34525 A UY34525 A UY 34525A
Authority
UY
Uruguay
Prior art keywords
medicinal product
formulation
inhalable medicinal
inhalable
percentages
Prior art date
Application number
UY0001034525A
Other languages
English (en)
Inventor
Xian-Ming Zeng
Original Assignee
Teva Branded Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45813952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34525(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products Inc filed Critical Teva Branded Pharmaceutical Products Inc
Publication of UY34525A publication Critical patent/UY34525A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN MEDICAMENTO INHALABLE Esta invención se refier e a una formulación en solución que comprende una sal de tiotropio, 12-20% de etanol, 0,1-1,5% de agua, 0,05-0,10% de ácido cítrico (u otro ácido orgánico) y un propelente de HFA, en donde los porcentajes son porcentajes en peso en base al peso total de la formulación. La invención también proporciona un pMDI que comprende una lata que contiene la formulación.
UY0001034525A 2011-12-19 2012-12-18 Un medicamento inhalable UY34525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577315P 2011-12-19 2011-12-19
GBGB1200525.2A GB201200525D0 (en) 2011-12-19 2012-01-13 An inhalable medicament

Publications (1)

Publication Number Publication Date
UY34525A true UY34525A (es) 2014-07-31

Family

ID=45813952

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034525A UY34525A (es) 2011-12-19 2012-12-18 Un medicamento inhalable

Country Status (29)

Country Link
US (1) US9655969B2 (es)
EP (3) EP3143998B1 (es)
JP (1) JP5791166B2 (es)
KR (2) KR101670564B1 (es)
CN (1) CN103998039A (es)
AR (1) AR089302A1 (es)
AU (1) AU2012358475B2 (es)
BR (1) BR112014014535A2 (es)
CA (1) CA2856047C (es)
CY (1) CY1116142T1 (es)
DK (3) DK3143998T3 (es)
EA (1) EA028461B1 (es)
ES (3) ES2728940T3 (es)
GB (1) GB201200525D0 (es)
HK (2) HK1198512A1 (es)
HR (1) HRP20141176T1 (es)
HU (2) HUE044647T2 (es)
IL (1) IL232946A0 (es)
MX (1) MX361925B (es)
PL (3) PL2793886T3 (es)
PT (1) PT2606891E (es)
RS (1) RS53783B1 (es)
SI (1) SI2606891T1 (es)
SM (1) SMT201400192B (es)
TR (1) TR201908429T4 (es)
TW (1) TWI468187B (es)
UY (1) UY34525A (es)
WO (1) WO2013092237A1 (es)
ZA (2) ZA201403041B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY156950A (en) 2009-12-23 2016-04-15 Chiesi Farma Spa Aerosol formulation for copd
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
EP2819669B1 (de) 2012-02-28 2021-04-21 Boehringer Ingelheim International GmbH Neue treibgashaltige tiotropium-formulierung
EP2897589B1 (en) * 2013-11-22 2018-01-03 Teva Branded Pharmaceutical Products R & D, Inc. An inhalable medicament
MX2016006377A (es) * 2013-11-22 2016-10-28 Teva Branded Pharmaceutical Products R&D Inc Un medicamento inhalable.
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
US20190054010A1 (en) * 2015-10-29 2019-02-21 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
EP3922240B1 (en) * 2016-09-19 2023-06-21 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
WO2020006017A1 (en) * 2018-06-27 2020-01-02 3M Innovative Properties Company Tiotropium formulation and inhaler

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9026191D0 (en) * 1990-12-01 1991-01-16 Harris Pharma Ltd Breath actuated dispensing device
EP0616525B1 (en) 1991-12-12 1995-09-27 Glaxo Group Limited Pharmaceutical aerosol formulation
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB2264238A (en) 1992-05-29 1993-08-25 Norton Healthcare Ltd Medicament inhalor device
AU680227B2 (en) * 1992-12-09 1997-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
EP1131059B1 (de) 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
EP1238661A1 (en) 1999-10-12 2002-09-11 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US6553988B1 (en) 2000-06-09 2003-04-29 Norton Healthcare, Inc. Medicament dispensing device with a multimaterial diaphragm bounding a pneumatic force chamber
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
ATE275391T1 (de) 2000-10-12 2004-09-15 Boehringer Ingelheim Pharma Neue tiotropium-haltige inhalationspulver
WO2002030928A1 (de) 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kristallines monohydrat, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
US20030070679A1 (en) 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
BR0210537A (pt) 2001-06-22 2004-06-22 Boehringer Ingelheim Pharma Anticolinérgico cristalino, processo para a sua preparação e sua aplicação para a preparação de um medicamento
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
DE10214263A1 (de) 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003303029A1 (en) * 2002-12-16 2004-07-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
US20050058606A1 (en) * 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US20070189979A1 (en) 2003-09-18 2007-08-16 Norton Healthcare Limited T/A Ivax Pharmaceuticals Particles
US7968717B2 (en) 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
AU2004285684B2 (en) 2003-11-03 2011-07-14 Boehringer Ingelheim International Gmbh Novel crystalline anhydride with anticholinergic effect
SE0303570L (sv) 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
WO2005086915A2 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US20060079544A1 (en) 2004-08-13 2006-04-13 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
EP1850831B1 (en) * 2005-02-25 2015-12-02 CHIESI FARMACEUTICI S.p.A. Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
JP2008540367A (ja) 2005-05-02 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
JP5227790B2 (ja) 2005-05-02 2013-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
EP1896026B1 (en) 2005-06-15 2013-10-09 Boehringer Ingelheim International GmbH Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
NZ566399A (en) 2005-08-06 2011-07-29 Boehringer Ingelheim Int Use of tiotropium salts in the treatment of severe persistant asthma
TWI389692B (zh) 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
CN102731494A (zh) 2005-12-19 2012-10-17 西科尔公司 噻托溴铵的新形式及其制备方法
EP1923393A1 (en) 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
EP2389162A1 (en) 2009-01-26 2011-11-30 Teva Pharmaceutical Industries Ltd Processes for coating a carrier with microparticles
DK2501363T3 (en) * 2009-11-17 2015-03-23 Cipla Ltd inhalable
SI2627386T1 (sl) 2010-10-12 2015-10-30 Ivax Pharmaceuticals Ireland Nosna pršilna naprava
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
GB201200504D0 (en) 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
EP2819669B1 (de) 2012-02-28 2021-04-21 Boehringer Ingelheim International GmbH Neue treibgashaltige tiotropium-formulierung

Also Published As

Publication number Publication date
IL232946A0 (en) 2014-07-31
ES2602314T3 (es) 2017-02-20
EP3143998B1 (en) 2019-05-22
EP2793886A1 (en) 2014-10-29
NZ624161A (en) 2015-08-28
AU2012358475A1 (en) 2014-05-22
HK1198512A1 (en) 2015-05-15
CY1116142T1 (el) 2017-03-15
DK2606891T3 (en) 2015-01-05
EP2793886B1 (en) 2016-08-24
DK2793886T3 (en) 2016-12-05
EP2606891B1 (en) 2014-11-05
RS53783B1 (en) 2015-06-30
SI2606891T1 (sl) 2015-04-30
KR20160111539A (ko) 2016-09-26
HUE044647T2 (hu) 2019-11-28
TR201908429T4 (tr) 2019-07-22
KR20140097481A (ko) 2014-08-06
ES2728940T3 (es) 2019-10-29
EP3143998A1 (en) 2017-03-22
HRP20141176T1 (hr) 2015-03-13
PL2606891T3 (pl) 2015-07-31
KR101670564B1 (ko) 2016-10-28
ES2526685T3 (es) 2015-01-14
CA2856047A1 (en) 2013-06-27
PT2606891E (pt) 2015-01-05
EA201491206A1 (ru) 2014-12-30
BR112014014535A2 (pt) 2017-06-13
PL3143998T3 (pl) 2019-09-30
HK1200343A1 (en) 2015-08-07
US9655969B2 (en) 2017-05-23
MX2014007357A (es) 2014-08-21
CA2856047C (en) 2017-01-03
JP5791166B2 (ja) 2015-10-07
HUE030983T2 (en) 2017-06-28
US20140348758A1 (en) 2014-11-27
TW201332587A (zh) 2013-08-16
TWI468187B (zh) 2015-01-11
AU2012358475B2 (en) 2015-08-20
WO2013092237A1 (en) 2013-06-27
DK3143998T3 (da) 2019-06-17
GB201200525D0 (en) 2012-02-29
ZA201403041B (en) 2015-11-25
EP2606891A1 (en) 2013-06-26
AR089302A1 (es) 2014-08-13
ZA201501986B (en) 2016-10-26
EA028461B1 (ru) 2017-11-30
SMT201400192B (it) 2015-03-05
PL2793886T3 (pl) 2017-06-30
MX361925B (es) 2018-12-19
CN103998039A (zh) 2014-08-20
AU2012358475A8 (en) 2014-06-26
JP2015500224A (ja) 2015-01-05

Similar Documents

Publication Publication Date Title
UY34525A (es) Un medicamento inhalable
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
DOP2012000011A (es) Formulacion farmaceutica
AR094204A1 (es) Composiciones para el cuidado oral que contienen haluros de acido amino
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
ECSP067054A (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
NI201200168A (es) Formulaciones farmacéuticas
WO2012016845A3 (en) Pharmaceutical formulation comprising a phosphodiesterase inhibitor
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
CL2020000944A1 (es) Compuestos bicíclicos y métodos de utilización de los mismos.
ECSP13012838A (es) Nuevos compuestos de benzodioxol-piperazina
GT201400042A (es) Compuesto de benzotiazolona
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
UY33299A (es) Derivados de 6-(alquil-o cicloalquil-triazolopiridacina-silfanil)benzotiazoles:preparacion, aplicación como medicamentos y utilizacion como inhibidores de la met
CL2013002353A1 (es) Uso de una composicion farmaceutica que contiene al menos un compuesto que contiene selenita y al menos un acido farmaceuticamente aceptable, util en la preparacion de un medicamento para el tratamiento de alteraciones celulares cervicales que tienen una calificacion pap de pap iii o pap iiid y/o una calificacion cin > o = a cin 1.
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
UY33240A (es) ?análogos de péptidos?.

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20150720